Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 17.91 is 198% above its 1-year average of 6.01, near the high end of its 1-year range (0.00–17.91).
As of the fiscal period ended Tuesday, June 30, 2026. 123.57% above its 12-month average of 8.01.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 17.91.
CURRENT RATIO
17.91
CURRENT RATIO AVG TTM
8.01
CURRENT RATIO AVG 3Y
N/A
CURRENT RATIO AVG 5Y
N/A
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+123.57%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.76
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+376.31%
vs the sector median at left
Market Cap
$3.38B
Current Ratio
3.39
TTM Avg
3.10
3Y Avg
3.17
5Y Avg
4.31
Market Cap
$3.31B
Current Ratio
4.72
TTM Avg
21.21
3Y Avg
17.30
5Y Avg
19.05
Market Cap
$3.48B
Current Ratio
10.45
TTM Avg
13.16
3Y Avg
14.41
5Y Avg
11.78
Market Cap
$3.52B
Current Ratio
3.87
TTM Avg
5.22
3Y Avg
3.96
5Y Avg
4.18
Market Cap
$3.54B
Current Ratio
21.02
TTM Avg
15.64
3Y Avg
20.34
5Y Avg
22.11
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. (PBLS) | $3.36B | 17.91 | 8.01 | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 3.39 | 3.10 | 3.17 | 4.31 |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | 4.72 | 21.21 | 17.30 | 19.05 |
| CareDx, Inc (CDNA)vs › | $3.30B | 4.58 | 3.40 | 3.98 | 4.25 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | 9.63 | 11.21 | 9.89 | 7.80 |
| Celcuity Inc. (CELC)vs › | $3.47B | 8.93 | 9.13 | 14.29 | 16.91 |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | 10.45 | 13.16 | 14.41 | 11.78 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | 3.87 | 5.22 | 3.96 | 4.18 |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | 21.02 | 15.64 | 20.34 | 22.11 |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 3.20 | 4.13 | 7.45 | 12.80 |
Current Ratio
17.91
Quick Ratio
17.91
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 17.91 |
| 2026-03-31 | 6.12 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
